Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Boadilla Del Monte – page 249

3 267 clinical trials in Boadilla Del Monte, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Boadilla Del Monte at a glance
3 267
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 267 trials in Boadilla Del Monte

Open in trial search

Tuberous sclerosis complex+1

Not recruiting

Study on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Radiprodil
  • Sponsor:Grin Therapeutics Inc.

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Class III or IV Lupus Nephritis

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:F. Hoffmann-La Roche AG

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Not recruiting

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986288
  • Sponsor:Bristol Myers Squibb International Corporation

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Solti Group

Myelofibrosis

Not recruiting

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fedratinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Neoplasm malignant+1

Not recruiting

Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

HIV infection

Not recruiting

Study Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

Non-small cell lung cancer stage IV+1

Not recruiting

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986315
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

K-ras gene mutation

Not recruiting

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Boadilla Del Monte

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development and immune responses for multiple infectious diseases, including studies of combination vaccines for childhood diseases and COVID-19 boosters.

  • MMRV Vaccine Studies
  • COVID-19 Booster Research
  • RSV Prevention

Special emphasis on pediatric populations and vaccine co-administration safety protocols.

02 Oncology Research

Comprehensive studies on various cancer types, with focus on pediatric liver cancers and innovative treatment approaches for solid tumors.

  • Hepatoblastoma Treatment
  • High-Grade Glioma Therapy
  • Prostate Cancer Management

Integration of targeted therapies and combination treatment protocols.

03 Cardiovascular Medicine

Investigations into cardiovascular disease prevention and treatment, particularly focusing on post-heart attack care and preventive measures.

  • ASCVD Prevention
  • Acute Coronary Syndrome
  • Cardiovascular Risk Management

Emphasis on long-term cardiovascular outcomes and preventive strategies.

04 Women's Health

Studies examining reproductive health and related conditions, including contraceptive efficacy and treatments for gynecological infections.

  • Contraceptive Development
  • Vaginal Health Studies
  • Treatment of Candidiasis

Focus on innovative delivery systems and treatment options.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.